

Organization **UNITED STATES PATENT AND TRADEMARK OFFICE**

United States Patent and Trademark Office

P.O. Box 1450


Alexandria, VA 22313-1450

If Undeliverable Return in Ten Days

OFFICIAL BUSINESS


PENALTY FOR PRIVATE USE, \$300

AN EQUAL OPPORTUNITY EMPLOYER



RETURN TO SENDER

RECEIVED
OCT 03 2006
USPTO MAIL CENTER



UNITED STATES PATENT AND TRADEMARK OFFICE

JW

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/758,524

01/15/2004

Jan G. Jaworski

07148-108002

5670

7590

09/21/2006

Scott R. Pribnow
Cargill, Incorporated
15407 McGinty Road West
Wayzata, MN 55391

EXAMINER

KAM, CHIH MIN

ART UNIT	PAPER NUMBER
----------	--------------

1656

DATE MAILED: 09/21/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.		Applicant(s)	
	10/758,524		JAWORSKI ET AL.	
	Examiner		Art Unit	
	Chih-Min Kam		1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2 and 8-11 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1,2 and 8-11 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 15 January 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>8/16/04</u> . | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

1. In the preliminary amendment filed January 15, 2004, claims 3-7 and 12-25 have been cancelled. Therefore, claims 1, 2 and 8-11 are examined.

Informalities

The disclosure is objected to because of the following informalities:

2. The specification recites amino acid sequences (e.g., GNTSSSS) at page 12, lines 19-21, without providing a sequence identifier "SEQ ID NO:". Applicants must comply with the requirements of the sequence rules (37 CFR 1.821-1.825) and provide a copy of sequence listing and CRF containing all the sequences.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

3. Claim 1 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim is drawn to a polypeptide. As written, the claim does not explicitly indicate the hand of man. Insertion of "isolated" or "purified" in connection with a polypeptide is suggested. See MPEP § 2105.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1656

4. Claims 1, 2 and 8-11 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1, 2 and 8-11 are directed to a polypeptide comprising in the amino-terminal to carboxy-terminal direction: a first polypeptide segment having membrane anchoring properties; joined to a second polypeptide segment having a sequence of residues 75-114 of SEQ ID NO:12 or 14; joined to a third polypeptide segment having at least 40% sequence identity to residues 115-506 of SEQ ID NO:4. The specification indicates the present invention provides polypeptide with altered elongase KCS (3-ketoacyl CoA synthase) substrate specificity and/or catalytic activity such as the peptides comprises three polypeptide segments, the amino-terminal first polypeptide segment having membrane anchoring properties, joined to a second polypeptide segment having a sequence of residues 75-114 of SEQ ID NO:12 or 14, followed by a third polypeptide segment having at least 40% sequence identity to the C-terminal 392 amino acids of SEQ ID NO:4 (residues 115-506), examples of such polypeptides have the sequences of SEQ ID NO:12 and 14 (page 3, lines 8-18; page 12, lines 5-9), where residues 115-506 of SEQ ID NO:12 and 14 having >99% sequence identity to the residues 115-506 of SEQ ID NO:4 (see attached sequence match), and the substrate specificity (C22:1/C20:1) of SEQ ID NO:12 or 14 resembles that of the wild-type Bn polypeptide (SEQ ID NO:4, Example 3; Tables 4 and 5). The specification further indicates the Bn G307D polypeptide had a higher elongase activity and produced more C22:1 product than the unmodified wild-type Bn polypeptide (SEQ ID NO:4; Example 4; Table 7). While a species of SEQ ID NO:12 and 14 for altered elongase KCS has

Art Unit: 1656

been disclosed, the specification does not describe a genus of variants for the third polypeptide segment of altered elongase KCS having at least 40% sequence identity to SEQ ID NO:4, and there is no disclosure of any particular structure to function/activity relationship in the disclosed species (i.e., polypeptides having at least 40% sequence identity to SEQ ID NO:4). Without guidance on the correlation of structure to function/activity of the third polypeptide segment of altered elongase KCS, one skilled in the art would not know which residues of the sequence are essential for function/activity. The lack of description on the structure to function/activity relationship of the third polypeptide segment in altered elongase KCS, and the lack of representative species as encompassed by the claims, applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise terms that a skilled artisan would not recognize applicants were in possession of the claimed invention.

Conclusion

5. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/758,524

Page 5

Art Unit: 1656

Chih-Min Kam, Ph. D.
Primary Patent Examiner



primary

CHIH-MIN KAM
PATENT EXAMINER

CMK

September 16, 2006

BLANK PAGE
NO DATA
SEQ ID NO

Db 175 NTNVPKDIIGILVNSSMFNPTSLSAMVNTFKLRNVSFNLGGMCSAGVIAIDLAK 234
Qy 121 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 180
Db 235 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 294
Qy 181 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 240
Db 295 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 354
Qy 241 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 300
Db 355 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 414
Qy 301 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 360
Db 415 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 474
Qy 361 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 392
Db 475 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 506

RESULT 3
US-09-877-476-14
Sequence 34, Application US/09877476
Patent No. 6713664

GENERAL INFORMATION:
APPLICANT: Jaworski, Jan G.
APPLICANT: Blacklock, Brenda J.
TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA
TITLE OF INVENTION: SYNTHASE POLYPEPTIDES
FILE REFERENCE: 07148-108001
CURRENT APPLICATION NUMBER: US/09/877,476
CURRENT FILING DATE: 2001-06-08
PRIOR FILING DATE: 2000-06-08
PRIOR FILING DATE: 2000-06-08
NUMBER OF SEQ ID NOS: 56
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 14:
LENGTH: 506
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: 5' 114 amino acids from A. thaliana FAE1 (SEQ ID NO:2) and 3' 392 amino acids from B. napus
OTHER INFORMATION: elongase KCS (SEQ ID NO:4), having a mutation at position 92; designated At114 K92R

US-09-877-476-14
Query Match 99.7%; Score 2031; DB 2; Length 506;
Best Local Similarity 99.7%; Pred. No. 1.5e-209;
Matches 391; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GTCDDSSWLDPLRKIQERSGLDTHGPEGLQVPPRKTFAAARETEQVIIGALENLFK 60
Db 115 GTCDDSSWLDPLRKIQERSGLDTHGPEGLQVPPRKTFAAARETEQVIIGALENLFK 174
Qy 61 NTNVPKDIIGILVNSSMFNPTSLSAMVNTFKLRNVSFNLGGMCSAGVIAIDLAK 120
Db 175 NTNVPKDIIGILVNSSMFNPTSLSAMVNTFKLRNVSFNLGGMCSAGVIAIDLAK 234
Qy 121 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 180
Db 235 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 294
Qy 181 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 240
Db 295 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 354
Qy 241 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 300


Db 355 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 414
Qy 301 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 360
Db 415 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 474
Qy 361 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 392
Db 475 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 506

RESULT 4
US-09-877-476-18
Sequence 18, Application US/09877476
Patent No. 6713664

GENERAL INFORMATION:
APPLICANT: Jaworski, Jan G.
APPLICANT: Blacklock, Brenda J.
TITLE OF INVENTION: FATTY ACID ELONGASE 3-KETOACYL COA
TITLE OF INVENTION: SYNTHASE POLYPEPTIDES
FILE REFERENCE: 07148-108001
CURRENT APPLICATION NUMBER: US/09/877,476
CURRENT FILING DATE: 2001-06-08
PRIOR FILING DATE: 2000-06-08
PRIOR FILING DATE: 2000-06-08
NUMBER OF SEQ ID NOS: 56
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 18:
LENGTH: 505
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: 5' 74 amino acids from A. thaliana FAE1 (SEQ ID NO:2) and 3' 431 amino acids from B. napus
OTHER INFORMATION: elongase KCS (SEQ ID NO:4) having a mutation at residue 306; designated At74 G306D; hypothetical

US-09-877-476-18
Query Match 99.7%; Score 2030; DB 2; Length 505;
Best Local Similarity 99.7%; Pred. No. 1.9e-209;
Matches 391; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GTCDDSSWLDPLRKIQERSGLDTHGPEGLQVPPRKTFAAARETEQVIIGALENLFK 60
Db 114 GTCDDSSWLDPLRKIQERSGLDTHGPEGLQVPPRKTFAAARETEQVIIGALENLFK 173
Qy 61 NTNVPKDIIGILVNSSMFNPTSLSAMVNTFKLRNVSFNLGGMCSAGVIAIDLAK 120
Db 174 NTNVPKDIIGILVNSSMFNPTSLSAMVNTFKLRNVSFNLGGMCSAGVIAIDLAK 233
Qy 121 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 180
Db 234 DLLHVHKTALVYSTENITNIYAGDNRSMVNSCLFRVGGAAILLNKPGDRRSKYE 293
Qy 181 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 240
Db 294 LVHTVTHTGADGKSFRCVQGGDDENGKIGVLSKDIITDVAGRTVKKNIAITLGPLILPLS 353
Qy 241 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 300
Db 354 EKLFFVTFMGKGLFKDKIKHYVVPDFKLAIDHFCIHAGGRAVIDVLEKNLALAPIDVEA 413
Qy 301 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 360
Db 414 SRSTLHFRGNTSSSIWYELAYIEAKGRMKGNKVMQIALGSGFKCNSAVVVALNNVKAS 473
Qy 361 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 392
Db 474 TNSPWEHCIDRYPVKIDSQSGKSETRVNGRS 505

RESULT 5
US-09-877-476-16



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07148-108002	Application No. 10/758,524
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Jan G. Jaworski et al.	
		Filing Date January 15, 2004	Group Art Unit 1638

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
CMK	AA	6,051,756	04/18/00	Chen et al.			
CMK	AB	6,124,524	09/26/00	James, Jr. et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CMK	AC	WO 95/15387	06/08/95	PCT				
	AD	WO 96/13582	05/09/96	PCT				
	AE	WO 98/46766	10/22/98	PCT				
	AF	WO 98/54954	12/10/98	PCT				
CMK	AG	WO 01/29238	04/26/01	PCT			Abstr.	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CMK	AH	GenBank Accession No. U29142
	AI	GenBank Accession No. U50771
	AJ	GenBank Accession No. AF009563
	AK	GenBank Accession No. AAA70154
	AL	GenBank Accession No. AAA96054
	AM	GenBank Accession No. AAB72178
	AN	GenBank Accession No. AAD22309
	AO	GenBank Accession No. CAA71898
	AP	GenBank Accession No. CAB36702
	AQ	"1999 Biochemistry and Molecular Biology of Plant Fatty Acids and Glycerolipids Symposium," National Plant Lipid Cooperative, June 9-13, 1999, South Lake Tahoe, California, P12, <i>Blacklock et al.</i>
	AR	Barret et al., "A rapeseed <i>FAT1</i> gene is linked to the E1 locus associated with variation in the content of erucic acid," <i>Theor. Appl. Genet.</i> , 1998, 96:177-186
	AS	Broun et al., <i>Science</i> , 1998, 282:131-133
CMK	AT	Clemens and Kunst, "Isolation of a <i>Brassica napus</i> cDNA (Accession No. AF009563) Encoding 3-Ketoacyl-CoA Synthase, a Condensing Enzyme Involved in the Biosynthesis of Very Long Chain Fatty Acids in Seeds," <i>Plant Physiol.</i> , 1997, 115:313-314

Examiner Signature /Chih Min Kam/	Date Considered 09/16/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07148-108002	Application No. 10/758,524
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Jan G. Jaworski et al.	
		Filing Date January 15, 2004	Group Art Unit 1638
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CMK	AU	Domergue et al., "Purification of the Acyl-CoA Elongase Complex from Developing Rapeseed and Characterization of the 3-Ketoacyl-CoA Synthase and the 3-Hydroxyacyl-CoA Dehydratase," <u>Lipids</u> , 2000, 35(5):487-494
	AV	Fiebig et al., "Alterations in <i>CER6</i> , a Gene Identical to <i>CUT1</i> , Differentially Affect Long-Chain Lipid Content on the Surface of Pollen and Stems," <u>Plant Cell</u> , 2000, 12:2001-2008
	AW	Fourmann et al., "The two genes homologous to <i>Arabidopsis FAE1</i> co-segregate with the two loci governing erucic acid content in <i>Brassica napus</i> ," <u>Theor. Appl. Genet.</u> , 1998, 96:852-858
	AX	Ghanevati and Jaworski, "Active-site residues of a plant membrane-bound fatty acid elongase β -ketoacyl-CoA synthase, <i>FAE1 KCS</i> ," <u>Biochim. Biophys. Acta</u> , 2001, 1530:77-85
	AY	Ghanevati, "Engineering and Mechanistic Studies of Fatty Acid Elongase1 β -Ketoacyl-CoA Synthase, <i>FAE1 KCS</i> ," A Dissertation, submitted to the Faculty of Miami University, Oxford, Ohio, 2000
	AZ	Han, " β -Ketoacyl-CoA Synthase Gene from <i>Brassica napus</i> L.: Functional Characterization and Promoter Analysis," A Dissertation, submitted to the University of Hamburg, Hamburg, 1999
	AAA	Han et al., "Functional characterization of β -ketoacyl-CoA synthase genes from <i>Brassica napus</i> L.," <u>Plant Mol. Biol.</u> , 2001, 46:229-239
	ABB	James, Jr., et al., "Directed Tagging of the <i>Arabidopsis FATTY ACID ELONGATION1 (FAE1)</i> Gene with the Maize Transposon <i>Activator</i> ," <u>Plant Cell</u> , 1995, 7:309-319
	ACC	Kunst et al., "Fatty acid elongation in developing seeds of <i>Arabidopsis thaliana</i> ," <u>Plant Physiol. Biochem.</u> , 1992, 30(4):425-434
	ADD	Lassner et al., "A Jojoba β -Ketoacyl-CoA Synthase cDNA Complements the Canola Fatty Acid Elongation Mutation in Transgenic Plants," <u>Plant Cell</u> , 1996, 8:281-292
	AEE	Millar and Kunst, "Very-long-chain fatty acid biosynthesis is controlled through the expression and specificity of the condensing enzyme," <u>Plant J.</u> , 1997, 12(1):121-131
	AFF	Millar et al., "Accumulation of Very-Long-Chain Fatty Acids in Membrane Glycerolipids Is Associated with Dramatic Alterations in Plant Morphology," <u>Plant Cell</u> , 1998, 11:1889-1902
	AGG	Millar and Kunst, "The natural genetic variation of the fatty-acyl composition of seed oils in different ecotypes of <i>Arabidopsis thaliana</i> ," <u>Phytochemistry</u> , 1999, 52:1029-1033
	AHH	Millar et al., " <i>CUT1</i> , an <i>Arabidopsis</i> Gene Required for Cuticular Wax Biosynthesis and Pollen Fertility, Encodes a Very-Long-Chain Fatty Acid Condensing Enzyme" <u>Plant Cell</u> , 1999, 11:825-838
	AII	Post-Beittenmiller, "Biochemistry and Molecular Biology of Wax Production in Plants," <u>Annu. Rev. Plant Physiol. Plant Mol. Biol.</u> , 1996, 47:405-430
	AJJ	Pruitt et al., "FIDDLEHEAD, a gene required to suppress epidermal cell interactions in <i>Arabidopsis</i> , encodes a putative lipid biosynthetic enzyme," <u>Proc. Natl. Acad. Sci. USA</u> , 2000, 97(3):1311-1316
	AKK	Roscoe et al., "Mutations in the <i>fatty acid elongation 1</i> gene are associated with a loss of β -ketoacyl-CoA synthase activity in low erucic acid rapeseed," <u>FEBS Letters</u> , 2001, 492:107-111
	ALL	Tillman and Bell, <u>J. Biol. Chem.</u> , 1986, 261:9144-9149
	AMM	Todd et al., " <i>KCS1</i> encodes a fatty acid elongase 3-ketoacyl-CoA synthase affecting wax biosynthesis in <i>Arabidopsis thaliana</i> ," <u>Plant J.</u> , 1999, 17(2):119-130
CMK	ANN	Van de Loo et al., "An oleate 12-hydroxylase from <i>Ricinus communis</i> L. is a fatty acyl desaturase homolog," <u>Proc. Natl. Acad. Sci. USA</u> , 1995, 96:6743-6747

Examiner Signature /Chih Min Kam/	Date Considered 09/16/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07148-108002	Application No. 10/758,524
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Jan G. Jaworski et al.	
		Filing Date January 15, 2004	Group Art Unit 1638
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CMK	AOO	Venkateswari et al., "Molecular Cloning and Characterization of <i>FATTY ACID ELONGATION1 (BjFAE1)</i> Gene of <i>Brassica juncea</i> ," <i>J. Plant Biochem. Biotech.</i> , 1999, 8:53-55
CMK	APP	Yephremov et al., "Characterization of the FIDDLEHEAD Gene of Arabidopsis Reveals a Link between Adhesion Response and Cell Differentiation in the Epidermis," <i>Plant Cell</i> , 1999, 11:2187-2201

Examiner Signature /Chih Min Kam/	Date Considered 09/16/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	